Macter International Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0113501016
PKR
386.10
-9.15 (-2.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Macter International Ltd. stock-summary
stock-summary
Macter International Ltd.
Pharmaceuticals & Biotechnology
Macter International Ltd is a Pakistan-based pharmaceutical company. The Company’s primary activity is to manufacture and market pharmaceutical products. It offers a diversified portfolio of pharmaceutical products covering all therapeutic categories including antibiotics, anti-allergy, cardiovascular and Anti-viral infections. Its offered product under various therapeutic categories, includes DX3 Softgel, Macdronic 5mg, Macdronic 4mg , MAclimta , Milast, MACIVY, MACLINZA, Avelia Sachet, SANTE IV, Maclusa, Nurica, Alenor, Atizox, Bismol, Buphain, Cadla, Carac, Carac-H, Co-Amoxi, Dexodine, Demeco, Dicaine, DX3 Softgel, Ecavir, Epilepsin, Epuram, Esante, Glio, Hart, Heberon Alfa R, Inspirol, Itogaurd, Lefanor, Locril, Locril Plus, Mac-Mether, Macprofen, Macdicol, Macticort, Mitaz, Proberry Probiotic Capsule, Sante Plus, Setzine, Sofomac, Tacip, tio-Veez and Zincasa.
Company Coordinates stock-summary
Company Details
F-216, S.I.T.E , KARACHI None : 75700
stock-summary
Tel: 92 21 32591000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Amanullah Kassim
Independent Non-Executive Chairman of the Board
Mr. Asif Misbah
Chief Executive, Executive Director
Mr. Swaleh Misbah Khan
Executive Director
Mr. Sheikh Aamir Naveed
Executive Director
Mr. Syed Anis Ahmad Shah
Director
Mr. Muhammad Chawla
Director
Mr. Tariq Wajid
Director
Ms. Masarrat Misbah
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,536 Million
(Quarterly Results - Mar 2025)
Net Profit:
91 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 15,392 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.62%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

22.19%

stock-summary
Price to Book

4.11